Method for producing RNA compositions
The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.
1. A method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, wherein the method comprises the steps of:
(a) providing a first liquid composition comprising at least one RNA,
(b) providing a second liquid composition comprising at least one cationic or polycationic compound, wherein the at least one cationic or polycationic compound is a cationic or polycationic peptide or a cationic or polycationic protein,
(c) introducing the first liquid composition and the second liquid composition into at least one reactor, wherein the first liquid composition and the second liquid composition are mixed with a blend time of 5 seconds or less, and
(d) recovering the product liquid composition comprising the nanoparticle comprising the at least one RNA and the at least one cationic or polycationic compound from the reactor.
2. The method according to claim 1 , wherein the at least one RNA is selected from the group consisting of a long-chain RNA, a coding RNA, a single-stranded RNA, a linear RNA, a messenger RNA (mRNA), an RNA oligonucleotide, an siRNA, an miRNA, an shRNA, an antisense RNA, a riboswitch, an immunostimulating RNA (isRNA), a ribozyme, an aptamer, a ribosomal RNA (rRNA), a transfer RNA (tRNA), a self-replicating RNA (replicon RNA), a CRISPR/Cas9 guide RNA, a small nuclear RNA (snRNA), a small nucleolar RNA (snoRNA), Piwi-interacting RNA (piRNA), a retroviral RNA, and a viral RNA (vRNA).
3. The method according to claim 1 , wherein the at least one RNA is a long-chain RNA comprising from 100 to 50000 nucleotides.
4. The method of claim 1 , wherein the at least one RNA is not an siRNA.
5. The method of claim 1 , wherein the at least one RNA is an mRNA.
6. The method of claim 1 , wherein the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound has a particle size of 300 nm or less.
7. The method of claim 1 , wherein the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound has a polydispersity index in a range from 0.05 to 0.50.
8. The method of claim 1 , wherein the product liquid composition comprising the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound is a stable colloidal dispersion in water of the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound.
9. The method of claim 1 , wherein the product liquid composition comprising the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound has absorption at 350 nm of 0.5 or less at a pathlength of 1 cm.
10. The method of claim 1 , wherein the product liquid composition comprising the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound has a turbidity of 100 FNU or less.
11. The method of claim 1 , wherein the first liquid composition comprises RNA in a concentration of from 0.1 to 20 g/L.
12. The method of claim 1 , wherein the at least one cationic or polycationic compound is selected from the group consisting of protamine, nucleoline, spermine or spermidine, poly-L-lysine (PLL), basic polypeptides, poly-arginine, oligoarginines, cell penetrating peptides (CPPs), HIV-binding peptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP22 derived or analog peptides, HSV VP22 (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, proline-rich peptides, arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia ), pAntp, pIsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB(1), pVEC, hCT-derived peptides, SAP, and histones.
13. The method of claim 1 , wherein the first liquid composition or the second liquid composition further comprise at least one compound selected from a salt or a lyoprotectant.
14. The method of claim 13 , wherein the first liquid composition or the second liquid composition comprise at least one salt selected from the group consisting of NaCl, KCl, LiCl, MgCl 2 , Nal, NaBr, Na 2 CO 3 , NaHCO 3 , Na 2 SO 4 , Na 3 PO 4 , KI, KBr, K 2 CO 3 , KHCO 3 , K 3 PO 4 , K 2 SO 4 , CaCl 2 , CaI 2 , CaBr 2 , CaCO 3 , CaSO 4 , Ca(OH) 2 , and Ca 3 (PO4) 2 .
15. The method of claim 1 , wherein the first liquid composition or the second liquid composition comprise at least one cation selected from the group consisting of Na + , K + , Li + , Mg 2+ , Ca 2+ , and Ba 2+ or at least one anion selected from the group consisting of Cl − , CO 3 2− , PO 4 3− and SO 4 2− .
16. The method of claim 15 , wherein the ratio of cation to RNA in the first liquid composition is from 3 to 30 mmol cation/g RNA.
17. The method of claim 1 , wherein the first liquid composition and the second liquid composition are added to the at least one reactor so that the at least one cationic or polycationic compound and the at least one RNA are present in the reactor with an N/P-ratio in a range from 0.1 to 10.
18. The method of claim 1 , further comprising a step (e) of isolating or concentrating the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound from the product liquid composition comprising the nanoparticle comprising at least one RNA and at least one cationic or polycationic compound.
19. The method of claim 1 , wherein the at least one RNA is selected from the group consisting of a non-coding RNA, a double-stranded RNA, and a circular RNA (circRNA).
20. The method of claim 1 , wherein the reactor comprises at least one dynamic mixing means.
21. The method of claim 1 , wherein the reactor comprises at least one static mixing means.
22. The method of claim 1 , wherein the reactor comprises at least one T-piece adapter.